Translocations involving chromosome 12p11-13, methotrexate metabolism, and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Clin Cancer Res 1998 Jan;4(1):183-8
Date
05/14/1998Pubmed ID
9516969Scopus ID
2-s2.0-0031930089 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
Children with B-progenitor cell acute lymphoblastic leukemia whose lymphoblasts at diagnosis accumulate high levels of methotrexate (MTX) and MTX polyglutamates (MTXPGs) appear to have a good prognosis. This has been attributed to increased sensitivity of their blast cells to MTX. However, the proportion of children who are cured of B-progenitor cell acute lymphoblastic leukemia exceeds the number whose lymphoblasts accumulate high MTXPG levels. We report that lymphoblasts from patients with < 50 chromosomes who have translocations that involve the short arm of chromosome 12 accumulate low levels of MTXPGs. These patients appear to have an excellent survival because none of 14 patients with translocations affecting 12p has relapsed, 26-79 months following diagnosis.
Author List
Whitehead VM, Vuchich MJ, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Bernstein ML, Akabutu JJ, Bowen T, Kamen BA, Watson MS, Look AT, Pullen DJ, Camitta BMESH terms used to index this publication - Major topics in bold
Antimetabolites, AntineoplasticChild
Child, Preschool
Chromosomes, Human, Pair 12
DNA-Binding Proteins
Female
Humans
Infant
Male
Methotrexate
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proto-Oncogene Proteins c-ets
Repressor Proteins
Transcription Factors
Translocation, Genetic
